Pulse Biosciences, Inc. (PLSE)
USD 17.83
(-7.33%)
USD 17.83
(-7.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -42.36 Million USD | 27.03% |
| 2022 | -56.7 Million USD | 7.87% |
| 2021 | -61.86 Million USD | -27.82% |
| 2020 | -48.87 Million USD | -5.36% |
| 2019 | -46.79 Million USD | -25.46% |
| 2018 | -36.65 Million USD | -48.31% |
| 2017 | -24.56 Million USD | -181.91% |
| 2016 | -8.82 Million USD | -137.83% |
| 2015 | -3.75 Million USD | -3373.12% |
| 2014 | -108 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -13.65 Million USD | -16.91% |
| 2024 Q2 | -11.46 Million USD | -10.78% |
| 2024 Q1 | -10.31 Million USD | 15.64% |
| 2023 FY | - USD | 27.03% |
| 2023 Q4 | -12.22 Million USD | -8.68% |
| 2023 Q3 | -11.25 Million USD | -10.02% |
| 2023 Q1 | -9.26 Million USD | -5.89% |
| 2023 Q2 | -10.22 Million USD | -10.44% |
| 2022 Q3 | -17.68 Million USD | -29.47% |
| 2022 Q2 | -13.66 Million USD | 19.4% |
| 2022 FY | - USD | 7.87% |
| 2022 Q1 | -16.94 Million USD | -9.97% |
| 2022 Q4 | -8.74 Million USD | 50.55% |
| 2021 Q2 | -14.52 Million USD | 20.39% |
| 2021 Q4 | -15.41 Million USD | -10.18% |
| 2021 Q1 | -18.24 Million USD | -34.25% |
| 2021 FY | - USD | -27.82% |
| 2021 Q3 | -13.98 Million USD | 3.7% |
| 2020 Q4 | -13.59 Million USD | -7.5% |
| 2020 Q1 | -11.68 Million USD | 14.49% |
| 2020 Q2 | -11.07 Million USD | 5.15% |
| 2020 Q3 | -12.64 Million USD | -14.12% |
| 2020 FY | - USD | -5.36% |
| 2019 Q1 | -10.24 Million USD | -15.17% |
| 2019 FY | - USD | -25.46% |
| 2019 Q4 | -13.66 Million USD | -16.68% |
| 2019 Q3 | -11.7 Million USD | -3.19% |
| 2019 Q2 | -11.34 Million USD | -10.76% |
| 2018 Q3 | -10.54 Million USD | -17.5% |
| 2018 Q2 | -8.97 Million USD | -6.81% |
| 2018 FY | - USD | -48.31% |
| 2018 Q1 | -8.4 Million USD | 3.0% |
| 2018 Q4 | -8.89 Million USD | 15.68% |
| 2017 Q2 | -6.05 Million USD | -97.13% |
| 2017 Q1 | -3.07 Million USD | -14.76% |
| 2017 Q3 | -7.21 Million USD | -19.13% |
| 2017 Q4 | -8.66 Million USD | -20.15% |
| 2017 FY | - USD | -181.91% |
| 2016 Q1 | -1.49 Million USD | -10.98% |
| 2016 FY | - USD | -137.83% |
| 2016 Q4 | -2.67 Million USD | -2.65% |
| 2016 Q3 | -2.6 Million USD | -25.88% |
| 2016 Q2 | -2.07 Million USD | -38.44% |
| 2015 Q4 | -1.34 Million USD | -27.65% |
| 2015 Q1 | -567 Thousand USD | -119.37% |
| 2015 Q3 | -1.05 Million USD | -35.38% |
| 2015 FY | - USD | -3373.12% |
| 2015 Q2 | -780 Thousand USD | -37.57% |
| 2014 Q4 | -258.47 Thousand USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -45.63 Million USD | 7.155% |
| AngioDynamics, Inc. | -14.29 Million USD | -196.439% |
| AtriCure, Inc. | -8.1 Million USD | -422.469% |
| Avinger, Inc. | -16.34 Million USD | -159.189% |
| Azenta, Inc. | 55.15 Million USD | 176.82% |
| BioLife Solutions, Inc. | -45.23 Million USD | 6.346% |
| The Cooper Companies, Inc. | 882.8 Million USD | 104.799% |
| Daxor Corporation | 329.74 Thousand USD | 12948.608% |
| Ekso Bionics Holdings, Inc. | -13.19 Million USD | -221.011% |
| Femasys Inc. | -13.16 Million USD | -221.708% |
| GlucoTrack, Inc. | -7.09 Million USD | -497.476% |
| Harvard Bioscience, Inc. | 9.49 Million USD | 546.297% |
| Hologic, Inc. | 1.29 Billion USD | 103.269% |
| ICU Medical, Inc. | 307.69 Million USD | 113.769% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 101.77% |
| KORU Medical Systems, Inc. | -9.39 Million USD | -350.732% |
| LeMaitre Vascular, Inc. | 48.99 Million USD | 186.481% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -544.352% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -544.352% |
| Masimo Corporation | 236.7 Million USD | 117.899% |
| Microbot Medical Inc. | -10.63 Million USD | -298.411% |
| Meihua International Medical Technologies Co., Ltd. | 15.77 Million USD | 368.646% |
| Merit Medical Systems, Inc. | 231.44 Million USD | 118.306% |
| Nephros, Inc. | -1.37 Million USD | -2972.299% |
| NovoCure Limited | -175.86 Million USD | 75.909% |
| NEXGEL, Inc. | -2.73 Million USD | -1451.905% |
| NEXGEL, Inc. | -2.73 Million USD | -1451.905% |
| Singular Genomics Systems, Inc. | -86.49 Million USD | 51.019% |
| OraSure Technologies, Inc. | 76.15 Million USD | 155.63% |
| Pro-Dex, Inc. | 8.33 Million USD | 608.424% |
| Predictive Oncology Inc. | -13.18 Million USD | -221.4% |
| Precision Optics Corporation, Inc. | -2.51 Million USD | -1586.617% |
| QuidelOrtho Corporation | 545.6 Million USD | 107.765% |
| Repligen Corporation | 124.29 Million USD | 134.087% |
| Sanara MedTech Inc. | -289.09 Thousand USD | -14554.943% |
| STAAR Surgical Company | 33.22 Million USD | 227.531% |
| Sharps Technology, Inc. | -8.98 Million USD | -371.772% |
| Utah Medical Products, Inc. | 24.8 Million USD | 270.8% |
| DENTSPLY SIRONA Inc. | 232 Million USD | 118.262% |
| Jin Medical International Ltd. | 3.44 Million USD | 1330.567% |